Entrada Therapeutics, Inc. - TRDA STOCK NEWS

Entrada Therapeutics (Nasdaq: TRDA) has appointed Dr. Bernhardt “Bernie” Zeiher to its Board of Directors. Previously, Dr. Zeiher was the Chief Medical Officer at Astellas Pharma, where he played key roles in developing numerous therapeutic products. His extensive experience in clinical and regulatory affairs is expected to benefit Entrada as it progresses its lead drug programs targeting Duchenne muscular dystrophy and myotonic dystrophy type 1. Dr. Zeiher expresses enthusiasm for joining during this growth phase, emphasizing his alignment with Entrada’s mission to innovate in intracellular therapeutics.

Entrada Therapeutics (Nasdaq: TRDA), a biopharmaceutical company, announced participation of CEO Dipal Doshi in a virtual fireside chat at the Guggenheim Genomic Medicines and Rare Disease Conference on April 4, 2023 at 9:00 a.m. ET. This event aims to highlight Entrada's innovative approach to Endosomal Escape Vehicle (EEV™) therapeutics, which targets previously inaccessible intracellular areas for drug delivery. Interested stakeholders can access the live webcast on Entrada's Investor Relations page, with a replay available for 90 days post-event.

Entrada is developing therapies for various diseases, including neuromuscular and immunological conditions, with specific focus on treatments for Duchenne muscular dystrophy.

Entrada Therapeutics (TRDA) has announced a collaboration with Vertex to develop Endosomal Escape Vehicle-therapeutics for myotonic dystrophy type 1. The company is actively addressing the FDA's clinical hold on its IND application for ENTR-601-44 and has selected ENTR-601-45 as a new therapeutic candidate for Duchenne muscular dystrophy. Following the Vertex collaboration, Entrada's cash runway has been extended into the second half of 2025. Financial results for Q4 2022 reveal a net loss of $24.6 million, up from $18.4 million in Q4 2021, with cash and equivalents totaling $188.7 million, down from $291.1 million a year prior.

Entrada Therapeutics (Nasdaq: TRDA) recently announced that its President and CEO, Dipal Doshi, will participate in the Neuromuscular and Bone Corporate Panel at the Cowen 43rd Annual Health Care Conference on March 8, 2023, at 2:10 p.m. ET in Boston, MA. The conference aims to discuss advancements in healthcare, particularly in biotechnology. A live webcast of the panel will be accessible on Entrada's Investor Relations website, with a replay available for 90 days post-event. Entrada specializes in Endosomal Escape Vehicle (EEV™) therapeutics, targeting previously inaccessible diseases, with a focus on neuromuscular disorders.

Entrada Therapeutics (Nasdaq: TRDA) has announced the successful closing of its strategic collaboration with Vertex following the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The agreement includes a $224 million upfront payment and a $26 million equity investment. Entrada could earn up to $485 million in milestone payments and royalties on future product sales. The collaboration focuses on ENTR-701, a candidate for treating myotonic dystrophy type 1 (DM1), and extends the company’s cash runway into the second half of 2025, enabling further development of its Endosomal Escape Vehicle (EEV™)-therapeutics.

Entrada Therapeutics announces the selection of ENTR-601-45 as a new clinical candidate for treating individuals with Duchenne muscular dystrophy who are amenable to exon 45 skipping. The biopharmaceutical company plans to submit an Investigational New Drug (IND) application in the second half of 2024. Initial studies demonstrate over 90% exon skipping in a hDMD mouse model. The company aims to address a significant unmet need in the Duchenne community and will present further data at the Muscular Dystrophy Association Clinical Conference in March 2023.

Entrada Therapeutics, Inc. (Nasdaq: TRDA) announced a clinical hold from the FDA on its IND application for ENTR-601-44, aimed at treating Duchenne muscular dystrophy. The FDA's formal Clinical Hold letter will be issued within 30 days. CEO Dipal Doshi expressed disappointment but is committed to addressing the FDA's concerns. The hold is significant as there are currently no approved therapies for patients with exon 44 skippable mutations in Duchenne. Further updates will follow as Entrada engages with the FDA.